Tag Lymphoma

Results from the VALENTINE-PTCL01 Phase 2 trial of EZHARMIA® showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma.

Results from the VALENTINE-PTCL01 phase 2 trial of Daiichi Sankyo’s EZHARMIA® (valemetostat tosilate) showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The data were presented in an oral session at the 2023…

New data from the ongoing Phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab demonstrated an ORR of 82 percent, a CR rate of 63 percent and MRD negativity rate of 67 percent in patients with R/R follicular lymphoma.

Genmab and AbbVie announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate…

World Lymphoma Awareness Day

World Lymphoma Awareness Day is observed annually on September 15 and serves as a dedicated occasion for increasing awareness about lymphoma, an increasingly prevalent type of cancer. This global initiative is hosted by the Lymphoma Coalition, a non-profit network organization…